LifeMD price to sales ratio LFMD

Market value divided by revenue over the last twelve months, since 2014.

Today, Oct 23, 2026: n/m; not a meaningful number
Last meaningful: 1.0×; May 2026
9-year median: 1.2×
9-year range: 0.3× to 20.4×
Peer median: 1.4×

LifeMD's price to sales ratio is not a meaningful number today: revenue for one or more of the four quarters through 2026-06-30 is missing, so twelve months can't be added up.

It was last meaningful in May 2026, at 1.0×.

On the days it had one over the last 9 years, its median was 1.2×, from 0.3× in Mar 2023 to 20.4× in Feb 2021.

Price to sales ratio over time

median 1.2×

The dashed line is the 9-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	1.0×	0.5×	1.0×
2025	0.7×	0.6×	2.9×
2024	1.2×	1.0×	3.3×
2023	2.3×	0.3×	2.4×
2022	0.5×	0.5×	1.6×
2021	1.5×	1.5×	20.4×
2020	4.5×	0.6×	9.4×
2019	0.6×	0.5×	1.1×
2018	1.0×	0.9×	2.6×
2017	n/m a value too high to mean anything
2016	n/m a value too high to mean anything
2015	4.3×	3.9×	8.6×
2014	4.3×	3.1×	9.3×

Against its peers

Companies in Healthcare nearest LifeMD's size, closest first, today.

Company	Price to sales ratio
LFMDLifeMD	n/m
KEQUKewaunee Scientific	0.3×
ICCCImmucell	3.0×
LFVNLifevantage	0.4×
SPROSpero Therapeutics	1.4×
APTAlpha Pro Tech	0.9×
PDEXPro DEX	2.6×
PLXProtalix BioTherapeutics	2.5×
NATRNatures Sunshine Products	0.4×
ATNMActinium Pharmaceuticals	n/m
ELMDElectromed	3.0×
Peer median	1.4×

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on LifeMD

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.